Aclaris Therapeutics ACRS In Process Research And Development Expense
In Process Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:InProcessResearchAndDevelopmentExpense.
The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's in process research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's in process research and development expense?
- Aclaris Therapeutics (ACRS) reported in process research and development expense of $21.73M in Q4 2024.
- How has Aclaris Therapeutics's in process research and development expense changed year-over-year?
- Aclaris Therapeutics's in process research and development expense increased by 1211.0% year-over-year, from $1.66M to $21.73M.
- What does in process research and development expense mean?
- Captures the costs associated with research and development projects that are currently in progress and have not yet reached technological feasibility. This expense highlights the company's investment in early-stage therapeutic candidates that do not yet have an alternative future use. It is a critical indicator of the company's long-term growth potential and its focus on building a pipeline of novel immuno-inflammatory treatments.